Page last updated: 2024-12-08
6-hydroxy-fad
Description
6-hydroxy-FAD : Flavin-adenine dinucleotide (FAD) in which the hydrogen at position 6 of the benzo[g]pteridinedione moiety is substituted by a hydroxy group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
ID Source | ID |
PubMed CID | 4369241 |
CHEBI ID | 40260 |
SCHEMBL ID | 23780928 |
MeSH ID | M0148451 |
Synonyms (19)
Synonym |
6-hydroxy-flavin-adenine dinucleotide |
6-hydroxyflavine-adenine dinucleotide |
DB02654 |
6-hydroxy-fad |
6-hydroxyflavin-adenine dinucleotide |
6-ho-fad |
adenosine 5'-(trihydrogen diphosphate) 5'->5'-ester with 6-hydroxyriboflavin |
[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl (2r,3s,4s)-2,3,4-trihydroxy-5-(6-hydroxy-7,8-dimethyl-2,4-dioxo-3,4-dihydrobenzo[g]pteridin-10(2h)-yl)pentyl dihydrogen diphosphate |
CHEBI:40260 |
6-hydroxyriboflavin 5'-(trihydrogen diphosphate) 5'->5'-ester with adenosine |
adenosine 5'-(3-{d-ribo-5-[6-hydroxy-7,8-dimethyl-2,4-dioxo-3,4-dihydrobenzo[g]pteridin-10(2h)-yl]-2,3,4-trihydroxypentyl} dihydrogen diphosphate) |
6-oh-fad |
6-hydroxy flavin adenine dinucleotide |
6-hydroxy-7,8-dimethyl-10-(ribityl-5'-adp)-isoalloxazine |
[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl (2r,3s,4s)-2,3,4-trihydroxy-5-(6-hydroxy-7,8-dimethyl-2,4-dioxo-3,4-dihydrobenzo[g]pteridin-10(2h)-yl)pentyl dihydrogen diphosphate (non-preferred name) |
Q41596256 |
Q27120393 |
SCHEMBL23780928 |
PD059898 |
Research
Studies (6)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 2 (33.33) | 18.7374 |
1990's | 2 (33.33) | 18.2507 |
2000's | 1 (16.67) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (16.67) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 6 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |